
Jiaxin Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3192170/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients. Rheumatology, 2015, 54, 1982-1990.	1.9	185
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. Clinical Infectious Diseases, 2022, 74, 734-742.	5.8	88
3	Clinical diagnosis and treatment of immune checkpoint inhibitorâ€associated pneumonitis. Thoracic Cancer, 2020, 11, 191-197.	1.9	52
4	Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China. Clinical Infectious Diseases, 2021, 73, e79-e85.	5.8	50
5	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitorâ€related hematological adverse events. Thoracic Cancer, 2020, 11, 799-804.	1.9	24
6	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology, 2021, 60, 2472-2477.	1.9	20
7	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer, 2020, 11, 810-818.	1.9	19
8	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. Arthritis Research and Therapy, 2019, 21, 44.	3.5	18
9	Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. Arthritis Research and Therapy, 2020, 22, 255.	3.5	18
10	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4â€related diseases: A prospective clinical trial. International Journal of Rheumatic Diseases, 2019, 22, 1479-1488.	1.9	17
11	Management of immune checkpoint inhibitorâ€related dermatologic adverse events. Thoracic Cancer, 2020, 11, 488-492.	1.9	17
12	Rheumatic immuneâ€related adverse events induced by immune checkpoint inhibitors. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 178-185.	1.1	17
13	Differences in clinical characteristics of IgC4-related disease across age groups: a prospective study of 737 patients. Rheumatology, 2021, 60, 2635-2646.	1.9	16
14	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	14
15	The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother‑neonate cohort study. Lancet Infectious Diseases, The, 2021, 21, 418-426.	9.1	14
16	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 21.	3.5	14
17	Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China. Rheumatology, 2018, 57, 2057-2059.	1.9	13
18	Use of glucocorticoids in the management of immunotherapyâ€related adverse effects. Thoracic Cancer, 2020_11_3047-3052	1.9	13

JIAXIN ZHOU

#	Article	IF	CITATIONS
19	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 171-175.	0.8	13
20	Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet's uveitis. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231984788.	2.5	12
21	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. Frontiers in Medicine, 2020, 7, 583944.	2.6	12
22	Management of immune checkpoint inhibitorâ€related adverse events: A review of case reports. Thoracic Cancer, 2020, 11, 498-504.	1.9	10
23	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 102.	3.5	10
24	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerging Microbes and Infections, 2021, 10, 2303-2312.	6.5	10
25	Clinical manifestation and management of immune checkpoint inhibitorâ€associated cardiotoxicity. Thoracic Cancer, 2020, 11, 475-480.	1.9	9
26	Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. Journal of Infection, 2020, 80, 310-319.	3.3	9
27	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110005.	2.1	9
28	The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease. Journal of Immunology Research, 2019, 2019, 1-7.	2.2	8
29	Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. Clinical Rheumatology, 2020, 39, 3449-3454.	2.2	8
30	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 2020, 11, 805-809.	1.9	8
31	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. Orphanet Journal of Rare Diseases, 2021, 16, 152.	2.7	8
32	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. EBioMedicine, 2021, 68, 103398.	6.1	8
33	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. Canadian Journal of Cardiology, 2021, 37, 895-903.	1.7	8
34	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. Frontiers in Immunology, 2021, 12, 747076.	4.8	7
35	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. Scientific Reports, 2020, 10, 6400.	3.3	6
36	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. Journal of Autoimmunity, 2021, 122, 102650.	6.5	6

JIAXIN ZHOU

#	Article	IF	CITATIONS
37	Clinical diagnosis and treatment of immune checkpoint inhibitorâ€associated adverse events in the digestive system. Thoracic Cancer, 2020, 11, 829-834.	1.9	5
38	Clinical diagnosis and treatment of immune checkpoint inhibitorsâ€related endocrine dysfunction. Thoracic Cancer, 2020, 11, 1099-1104.	1.9	5
39	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease. Rheumatology, 2022, 61, 815-825.	1.9	5
40	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort. Frontiers in Medicine, 2021, 8, 784520.	2.6	5
41	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clinical Rheumatology, 2021, 40, 4589-4596.	2.2	4
42	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. Rheumatology, 2021, 60, 3252-3261.	1.9	4
43	Clinical features and longâ€ŧerm outcomes of Chinese patients with scleroderma renal crisis. International Journal of Rheumatic Diseases, 2020, 23, 1194-1200.	1.9	3
44	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. Frontiers in Immunology, 2021, 12, 580271.	4.8	3
45	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4–related disease. Rheumatology, 2022, 61, 2197-2209.	1.9	3
46	SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology, 2022, 61, 1841-1848.	1.9	3
47	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmology, 2021, 21, 447.	1.4	3
48	Prediction of new organ onset in recurrent immunoglobulin G4–related disease during 10Âyears of followâ€up. Journal of Internal Medicine, 2022, 292, 91-102.	6.0	3
49	Management of immune checkpoint inhibitorâ€related rheumatic adverse events. Thoracic Cancer, 2020, 11, 198-202.	1.9	2
50	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis. Clinical Rheumatology, 2022, , 1.	2.2	2
51	Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. Rheumatology, 2022, 61, e277-e279.	1.9	2
52	The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	2
53	Risk and prognosis factors for systemic sclerosis with lung cancer: A singleâ€centre caseâ€control study in China. International Journal of Clinical Practice, 2021, 75, e13819.	1.7	1
54	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobin G4-related disease. Chinese Medical Journal, 2021, Publish Ahead of Print, .	2.3	0